BRIDGEWATER, N.J., Feb. 26 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) SoloSTAR(R ...
About the Study The approval of Apidra (R) for pediatric use is based upon a 26-week, phase III, open-label, active control study of Apidra (R) in comparison with insulin lispro in 572 children and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback